Translating Genetic Knowledge Into Clinical Care in Non-Autoimmune Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

6500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-06

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of TRANSLATE is to implement genetic information directly into patient care to improve diagnosis and treatment of non-autoimmune diabetes. This project is the first large-scale implementation of systematic genetic testing within a common, non-communicable, chronic disease in Denmark, and will spearhead efforts to advance personalized medicine in Denmark.

The project will contribute to establishing technology, workflow, and evidence on how to implement and communicate actionable genetic information to clinicians and patients in a generalized format. These developments are pivotal for personalized medicine to reach broader clinical application.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Variants and Phenotypic Characteristics of Patients With T2DM

NCT00760292

Type 2 Diabetes Mellitus

UNKNOWN

Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications

NCT02212522

Diabetes Mellitus Insulin-Dependent

UNKNOWN

Gene Expression Profiling and Bioinformatic Analysis Identifying Genes and Biochemical Pathways in Type 2 Diabetes

NCT00143013

Type 2 Diabetes

UNKNOWN

Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus

NCT04113239

Diabetes Mellitus, Type 2 Metagenome Genetic Predisposition

COMPLETED

Common Genetic Variation and Type 2 Diabetes

NCT00707616

Pre-diabetes

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TRANSLATE project is an integrative project with multifaceted goals, that can be broken down into two main columns. The foundation for both columns is the WGS analysis in a clinical diagnostic setting in order to guide patient treatment. Patients are not randomized and the inclusion and exclusion criteria are deliberately broad and minimal, respectively.

The first column is the clinical development project, which seeks to complete a novel diagnostic process. This column will develop new pipelines and uncover barriers and challenges associated with gene-based precision medicine to facilitate sustainable implementation of gene-based precision medicine beyond the TRANSLATE project.

During the project, we wish to focus on potential barriers against a broad application of gene-based precision medicine in a common disease. These may include:

* Challenges pertaining to the selection of variants that are deemed clinically actionable, automation of genetic interpretation/translation, and the feasibility of large-scale precision medicine implementation
* Ethical concerns of patients, clinicians, and other technicians with regard to the application and utility of genetic information
* Validity and limitations of current computational pipelines for variant calling including the calling of structural variants and aggregate genetic tools
* Challenges regarding the interoperability of IT systems and databases nationally in Denmark, specifically how central databases can be linked to clinical end-users
* How implementation of genetic analyses affects clinical decision-making and/or clinical trajectories, both qualitatively and quantitatively

The second column is a register-based research project in which we will utilize data from the patients to advance gene-based precision medicine. In this column we will both address how to establish comprehensive research infrastructure, as well as answer specific research questions. We will address how to combine and harmonize genetic data with other Danish registry sources. We will use the newly established methodologies to focus on the following research areas with respect to patient stratification, clinical trajectories, complication development, and other clinically relevant outcomes:

* Polygenic risk scores
* Machine learning algorithms
* Combined polygenic and monogenic traits
* Non-coding variation
* Structural variation, specifically exon deletions and duplications, which have previously been shown as a cause of monogenic diabetes

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Diabetes, Gestational

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with non-autoimmune diabetes (type 2 diabetes)

Any case of non-T1D defined as:

* Debut \>30 years of age OR
* Debut \<30 years of age AND negative autoantibodies

treated at Steno Diabetes Center Copenhagen

Whole genome sequencing

Intervention Type OTHER

Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.

Patients with gestational diabetes

Any case of diabetes diagnosed in pregnancy treated at the following obstetric clinics in the Capital Region in Denmark:

Rigshospitalet, Nordsjællands Hospital, Herlev Hospital, Hvidovre Hospital

Whole genome sequencing

Intervention Type OTHER

Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whole genome sequencing

Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

WGS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any case of non-T1D defined as debut \>30 years of age, OR debut \<30 years of age AND negative autoantibodies
* Any case of diabetes diagnosed in pregnancy (obstetric departments)